Generation of an induced pluripotent stem cell line (EURACi005-A) from a Parkinson's disease patient carrying a homozygous exon 3 deletion in the PRKNgene.


Journal

Stem cell research
ISSN: 1876-7753
Titre abrégé: Stem Cell Res
Pays: England
ID NLM: 101316957

Informations de publication

Date de publication:
12 2019
Historique:
received: 31 07 2019
revised: 01 10 2019
accepted: 11 10 2019
pubmed: 13 11 2019
medline: 27 6 2020
entrez: 13 11 2019
Statut: ppublish

Résumé

Mutations in the PRKN gene, encoding parkin, are the most frequent known cause of recessive Parkinson's disease (PD). We report the generation of an induced pluripotent stem cell (iPSC) line of a patient carrying a homozygous deletion of exon 3 in the PRKN gene. Skin fibroblasts were reprogrammed using non-integrating episomal plasmids. The generated cell line (EURACi005-A; iPS-2011) exhibits expression of pluripotency markers, the potential to differentiate into all three germ layers, and a stable karyotype. This iPSC line provides a valuable resource for further research on the pathomechanism and drug testing for PRKN-linked PD.

Identifiants

pubmed: 31715428
pii: S1873-5061(19)30254-5
doi: 10.1016/j.scr.2019.101624
pii:
doi:

Substances chimiques

Ubiquitin-Protein Ligases EC 2.3.2.27
parkin protein EC 2.3.2.27

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101624

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Alessandra Zanon (A)

Institute for Biomedicine, Eurac Research, via Galvani 31, Bolzano 39100, Italy. Electronic address: alessandra.zanon@eurac.edu.

Diana Riekschnitz (D)

Institute for Biomedicine, Eurac Research, via Galvani 31, Bolzano 39100, Italy.

Michael von Troyer (M)

Institute for Biomedicine, Eurac Research, via Galvani 31, Bolzano 39100, Italy.

Claudia Volpato (C)

Institute for Biomedicine, Eurac Research, via Galvani 31, Bolzano 39100, Italy.

Anne Picard (A)

Institute for Biomedicine, Eurac Research, via Galvani 31, Bolzano 39100, Italy.

Chiara Cantaloni (C)

Institute for Biomedicine, Eurac Research, via Galvani 31, Bolzano 39100, Italy.

Marina Di Segni (M)

Laboratory of Medical Genetics, Fondazione IRCCS Ca´ Granda, Ospedale Maggiore Policlinico, Milano, Italy.

Rosamaria Silipigni (R)

Department of Neurology, University of Lübeck, Lübeck, Germany.

Peter P Pramstaller (PP)

Institute for Biomedicine, Eurac Research, via Galvani 31, Bolzano 39100, Italy; Department of Neurology, University of Lübeck, Lübeck, Germany.

Andrew A Hicks (AA)

Institute for Biomedicine, Eurac Research, via Galvani 31, Bolzano 39100, Italy.

Irene Pichler (I)

Institute for Biomedicine, Eurac Research, via Galvani 31, Bolzano 39100, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH